Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Arizona.
Press releases published on August 8, 2025
XORTX Completes USD $114,500 Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 08, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late- …
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements and Implementation of Cease Trade Order
Not for dissemination in the United States of America VANCOUVER, British Columbia, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Aja Health and Wellness Inc. ("Aja" or the "Company") (TSXV:Aja) announces that the Alberta Securities Commission (the "ASC"), as its …
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a securities purchase agreement with …
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee …
Earth Science Tech, Inc. Reports 61% Asset Growth to $7.69 Million and $8.7 Million in First Quarter Revenue Following Foundational Quarter of Strategic Acquisitions
MIAMI, FL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- MIAMI, FL – August 8, 2025 – Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on acquiring and scaling high-potential operating businesses, today announced its …
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and …
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today …
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane expression; IND …
Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea U.S. Commercialization Officially Launched Mont-Saint-Guibert, Belgium – August 8, 2025, 10:10pm CET / 4:10pm ET – …
Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® Destiné au Traitement de l'Apnée Obstructive du Sommeil
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Nyxoah Obtient l'Autorisation de la FDA pour le Système Genio® Destiné au Traitement de l'Apnée Obstructive du Sommeil Lancement Officiel de la Commercialisation aux États-Unis Mont-Saint-Guibert, …
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update
Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for Research in Vision and Ophthalmology Annual Meeting and …
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – Vepdegestrant is the first PROteolysis TArgeting Chimera ( …
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options …
Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025
NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hyperion Defi, Inc. (NASDAQ: HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury …
Amwell makes grant to new employees under inducement plan
BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading technology-enabled care platform provider, announces that on August 8, Amwell made grants of RSUs covering an aggregate of 76,198 shares of its Class A common stock to two new …
Heartland Physio Unveils The R.E.A.L. Recovery Experience for Singapore’s Active Professionals
Singapore, Singapore, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Heartland Physio is proud to unveil its signature R.E.A.L. Recovery™ Experience, a therapist-led physiotherapy model designed for active professionals who are tired of machine-based treatments and one …
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an …
U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
This press release is not intended for UK media. HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 75% (N=71), as demonstrated in the Beamion-LUNG 1 clinical trial1 Accelerated approval follows Priority Review and …
Bringing Advanced Vascular Diagnostics to the Western US with the SmartVascular Dx™ Test
IRVINE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, …
Longeveron Announces Up To $17.5 Million Public Offering
MIAMI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related …